Cardiff Oncology, Inc.

NasdaqCM:CRDF Rapport sur les actions

Capitalisation boursière : US$67.8m

Cardiff Oncology Gestion

Gestion contrôle des critères 2/4

Le PDG Cardiff Oncology est Mani Mohindru, nommé en Jan2026, a un mandat de moins d'un an. détient directement 0.086% des actions de la société, d'une valeur de $ 58.59K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 0.6 ans et 12 ans.

Informations clés

Mani Mohindru

Directeur général

US$183.7k

Rémunération totale

Pourcentage du salaire du PDGn/a
Durée du mandat du directeur généralless than a year
Propriété du PDG0.09%
Durée moyenne d'occupation des postes de directionless than a year
Durée moyenne du mandat des membres du conseil d'administration12yrs

Mises à jour récentes de la gestion

Recent updates

Seeking Alpha • Jun 27

Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity

Summary Cardiff Oncology's recent trial data readout delay has unnerved the market, but I see this as a potential buying opportunity for speculative investors. Leadership change is not a major risk factor. The new CMO's pedigree suggests confidence in the company's prospects ahead of the catalyst. The delay could suggest an attempt to improve poor data, or an ability to add to already strong data by waiting for more patient second scans. Short interest is high, increasing volatility and squeeze potential if trial data is strong, but also signaling caution from sophisticated investors. CRDF's cash runway is sufficient for the near-term catalyst; I hold call options expecting momentum to return, as the July 29th readout date approaches. Read the full article on Seeking Alpha
Article d’analyse • May 21

Is Cardiff Oncology (NASDAQ:CRDF) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Feb 18

Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib

Summary Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC, with a strong therapeutic profile and potential for high returns if approved. Onvansertib's Phase II results indicate superior efficacy in first-line treatment, supporting Cardiff's financial stability and long-term investment potential. The competitive landscape includes therapies like LUMAKRAS and KRAZATI, but Onvansertib's mutation-agnostic approach offers a unique advantage. Despite high risks, Cardiff's cash runway and positive clinical data justify a "Strong Buy" rating for high-risk tolerant long-term investors. Read the full article on Seeking Alpha
Seeking Alpha • Dec 12

Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning

Summary Cardiff Oncology's phase 2 trial of onvansertib in mCRC shows promising preliminary data, with improved response rates in a dose-dependent manner. Onvansertib appears well tolerated and effective when combined with standard chemotherapy and bevacizumab, but patient numbers remain low, necessitating further validation. Financially, CRDF's equity raise extends their cash runway, supporting the continued development and reducing immediate financial risk. Despite uncertainties, I maintain a Buy rating, anticipating onvansertib's potential to significantly impact first-line RAS-mutant mCRC therapy. Read the full article on Seeking Alpha
Seeking Alpha • Nov 07

Cardiff Oncology: Some Data Are In; Here's What You Should Know And Look For Next

Summary Cardiff Oncology's main focus is onvansertib, a PLK1 inhibitor, showing promise in metastatic colorectal cancer, especially in bevacizumab-naive patients. CRDF-004 phase 2 trial's results are crucial for Cardiff's future, with data expected within two months, potentially informing a pivotal phase 3 trial. Financially, Cardiff has a cash runway of 5-6 quarters, but will need additional funding, potentially leading to significant shareholder dilution. While optimistic about onvansertib's potential, I caution investors due to the high-risk nature and uncertain outcomes of the upcoming trial results. Read the full article on Seeking Alpha
Article d’analyse • Oct 09

We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 04

Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market

Summary Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated metastatic colorectal cancer, potentially opening a massive market with an estimated $567 million to $3.78 billion in annual US sales. Onvansertib has demonstrated superior efficacy and safety over historical controls and competitors, particularly in bevacizumab-naïve patients, with impressive objective response rates and progression-free survival. Positive data from the ongoing CRDF-004 trial could lead to significant upside for Cardiff, attracting potential partnerships or acquisition interest from big pharma, including Pfizer. Cardiff's strong financial position, low cash burn, and favorable analyst ratings make it a compelling buy, with substantial growth potential in the mCRC market and beyond. Read the full article on Seeking Alpha
Article d’analyse • Jun 19

We're Hopeful That Cardiff Oncology (NASDAQ:CRDF) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Mar 09

Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)

Summary Cardiff Oncology is focused on developing a drug for colorectal cancer and pancreatic cancer, with promising early activity shown in colorectal cancer patients. The company is now focused on moving their drug to the first-line setting and has started a clinical trial to evaluate its efficacy. Cardiff Oncology has a strong financial position with enough funds to operate through Q3 2025, but the success of their drug is heavily dependent on the outcomes of a single trial. Read the full article on Seeking Alpha
Article d’analyse • Mar 03

We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Article d’analyse • Nov 16

Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

PDG

Mani Mohindru (54 yo)

less than a year
Titularisation
US$183,670
Compensation

Dr. Mani Mohindru, Ph D., is Co-Founder, President and Director of Roshon Therapeutics. She had been Interim Chief Executive Officer at Cardiff Oncology, Inc. since January 27, 2026 until April 09, 2026 an...

Équipe de direction

NomPositionTitularisationCompensationPropriété
Mani Mohindru
Presidentless than a yearUS$183.67k0.086%
$ 58.6k
Roger Sidhu
Chief Medical Officer1.2yrsUS$2.47m0%
$ 0
Josh Muntner
Chief Financial Officerless than a yearpas de données0.00073%
$ 495.1
Ajay Aggarwal
Chief Operating Officerless than a yearpas de donnéespas de données
Brigitte Lindsay
Chief Accounting Officerless than a yearpas de données0.040%
$ 27.2k
Tod Smeal
Chief Scientific Officer4.6yrsUS$4.17mpas de données
Elizabeth Anderson
VP of Finance & Administration11.1yrspas de donnéespas de données
0.6yrs
Durée moyenne de l'emploi
57yo
Âge moyen

Gestion expérimentée: L'équipe de direction de CRDF n'est pas considérée comme expérimentée (ancienneté moyenne 0.6 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Mani Mohindru
President5.2yrsUS$183.67k0.086%
$ 58.6k
Charles Cantor
Member of Scientific Advisory Boardno datapas de donnéespas de données
Gary Pace
Independent Director6.3yrsUS$184.17k3.02%
$ 2.0m
K. Hirth
Member of Scientific Advisory Board12yrspas de donnéespas de données
Paul Billings
Member of Scientific Advisory Board13.8yrsUS$35.85kpas de données
Rodney Markin
Independent Chairman of the Board12.5yrsUS$225.67k0.045%
$ 30.8k
Carlo Croce
Member of Scientific Advisory Boardno datapas de donnéespas de données
Riccardo Dalla-Favera
Member of Scientific Advisory Board16.3yrspas de donnéespas de données
Lale White
Independent Director6.3yrsUS$189.17k0.17%
$ 112.9k
Alberto Bardelli
Member of Scientific Advisory Board11.9yrspas de donnéespas de données
Renee Tannenbaum
Independent Director5.2yrsUS$181.67k0.029%
$ 19.8k
Brunangelo Falini
Member of Scientific Advisory Board16.3yrspas de donnéespas de données
12.0yrs
Durée moyenne de l'emploi
74yo
Âge moyen

Conseil d'administration expérimenté: Le conseil d'administration de la CRDF est chevronné et expérimenté ( 12 années d'ancienneté moyenne).

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/08/10 16:36
Cours de l'action en fin de journée2026/08/07 00:00
Les revenus2026/03/31
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Cardiff Oncology, Inc. est couverte par 14 analystes. 9 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Paul KnightBrean Capital Historical (Janney Montgomery)
Bryan BrokmeierCantor Fitzgerald & Co.
Gum-Ming LoweCraig-Hallum Capital Group LLC